Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711995 | 1.00 | ALDH1A1 (0.35) | ALDH1A1ADRA2ASMN1; SMN2EPHX1ALOX5 | |
| SCHEMBL9918702 | 0.81 | ALOX5 (0.38) | ADRA2AEPHX1ALOX5 | |
| SCHEMBL1238560 | 0.79 | ALOX5 (0.39) | ALDH1A1ADRA2AEPHX1ALOX5 | |
| SCHEMBL30786309 | 0.72 | EPHX1 (0.33) | ALDH1A1EPHX1ALOX5 | |
| SCHEMBL102998 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL27354002 | 0.71 | BRD4 (0.33) | ALDH1A1EPHX1ALOX5 | |
| SCHEMBL9614594 | 0.70 | ALDH1A1 (0.50) | ALDH1A1ADRA2ASMN1; SMN2EPHX1 | |
| SCHEMBL9614593 | 0.70 | ALDH1A1 (0.50) | ALDH1A1ADRA2ASMN1; SMN2EPHX1 | |
| Acetamide SCHEMBL9143780 | 0.69 | — | — | |
| SCHEMBL2606335 | 0.69 | EPHX1 (0.38) | EPHX1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624117-B2 | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250352655-A1 | THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USE | UNIV OKLAHOMA (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4648792-A2 | ANTI-TNFR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025217240-A1 | ANTI-TNFR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12433876-B2 | Septin inhibitors for treatment of cancers | UNIVERSITY OF ROCHESTER (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250289878-A1 | SURFACE-MODIFIED EXOSOMES AND METHODS OF USE | UNIV OKLAHOMA (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250243290-A1 | AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES | THE GENERAL HOSPITAL CORPORATION | 2025-07-31 | — | — | US | disclosed |
| WO-2025122817-A1 | ANTAGONISTIC CD40 ANTIBODIES | THE GENERAL HOSPITAL CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250179203-A1 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | THE GENERAL HOSPITAL CORPORATION | 2025-06-05 | — | — | US | disclosed |
| EP-3447075-B1 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES | MASSACHUSETTS GEN HOSPITAL (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230130754-A1 | SURFACE-MODIFIED EXOSOMES AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2023-04-27 | — | — | US | disclosed |
| US-20220395578-A1 | THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USE | UNIV OKLAHOMA (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220348645-A1 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220280491-A1 | SEPTIN INHIBITORS FOR TREATMENT OF CANCERS | THE UNIVERSITY OF ROCHESTER | 2022-09-08 | — | — | US | disclosed |
| WO-2022159675-A2 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES | THE GENERAL HOSPITAL CORPORATION (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-4021894-A1 | SEPTIN INHIBITORS FOR TREATMENT OF CANCERS | University of Rochester (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220112299-A1 | AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES | THE GENERAL HOSPITAL CORPORATION | 2022-04-14 | — | — | US | disclosed |
| US-20220098263-A1 | TUMOR NECROSIS FACTOR SUPERFAMILY AND TNF-LIKE LIGAND MUTEINS AND METHODS OF PREPARING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION | 2022-03-31 | — | — | US | disclosed |
| WO-2010084100-A1 | SOLUBLE ICAM-1 AS BIOMARKER FOR PREDICTION OF THERAPEUTIC RESPONSE | TRANSGENE SA (FR) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280491-A1 | SEPTIN INHIBITORS FOR TREATMENT OF CANCERS | SEPTIN2, SEPTIN8, SEPTIN7 | ALDH1A1 4000/4885ADRA2A 4625/4885SMN1; SMN2 3584/4885 |
| US-12624117-B2 | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides | TNFRSF9, TNFRSF1A, TNFSF11 | ALDH1A1 4655/4885ADRA2A 2414/4885SMN1; SMN2 4386/4885 |
| US-12433876-B2 | Septin inhibitors for treatment of cancers | SEPTIN2, SEPTIN8, SEPTIN7 | ALDH1A1 4000/4885ADRA2A 4625/4885SMN1; SMN2 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.